Sonova Sharpens Strategy with Divestment and Medical Focus

Sonova divests Sennheiser headphone business to sharpen focus on hearing aids and cochlear implants. Near-term outlook is subdued, but company sets ambitious 2031 revenue target.

The Swiss hearing solutions group Sonova has announced a major strategic pivot, deciding to divest its consumer audio division to concentrate exclusively on its medical hearing technology businesses. This refocused approach is designed to propel the company into new revenue territories by the end of the decade. However, a concurrent trading update indicates near-term momentum in the current fiscal year remains subdued.

Strategic Realignment and Financial Outlook

Central to Sonova's new direction is the planned sale of its consumer hearing arm, which includes the Sennheiser headphone business. Following an internal review, management has committed to channeling all resources toward its core medical segments: hearing aids and cochlear implants. This move is intended to optimize capital allocation and intensify the company's focus on technological innovation within its primary market.

Operationally, the wholesale segment recently demonstrated solid growth dynamics, allowing Sonova to capture additional market share. Despite this, the immediate environment continues to present challenges. For the 2025/26 fiscal year, the company now anticipates that both revenue and normalized EBITA will land at the lower end of their previously guided ranges. These ranges were 5% to 9% for revenue growth and 14% to 18% for normalized EBITA growth.

Long-Term Ambitions Set for 2031

Notwithstanding the current cautious outlook, Sonova has established ambitious medium-term financial targets. The company aims to achieve sustainable scaling of its business through enhanced market penetration and technological advancements.

Key medium-term financial objectives:
- Annual revenue growth: 5–10 %
- Core EBIT growth: 7–12 %
- Revenue target by 2030/31: 6 billion CHF

Share Price Performance Reflects Caution

The market's initial reaction to these strategic shifts has been muted. Since the start of the year, Sonova's share price has declined by approximately 16.44 percent. On Monday, the equity touched a new 52-week low of 183.40 euros before staging a minor recovery. The stock closed yesterday's session at 188.25 euros, remaining significantly below its 200-day moving average of around 232 euros.

Investors will gain a clearer picture of the strategic refocusing progress when Sonova publishes its full-year results for fiscal 2025/26 on May 18, 2026. Until that date, the latest trading update will serve as the primary reference for the market.